Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia

Emergency Medicine Journal

Volumn 28, Issue 2, 2011, Pages 122-127

  Jeong, Ki Young ^a   Kim, Kyuseok ^a   Kim, Tae Yun ^a   Lee, Christopher C ^b   Jo, Si On ^c   Rhee, Joong Eui ^a   Jo, You Hwan ^a   Suh, Gil Joon ^c   Singer, Adam J ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; UREA;

ADULT; AGED; APACHE; ARTICLE; BLOOD PRESSURE; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; FEMALE; HEART FAILURE; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONPARAMETRIC TEST; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; SURVIVAL; SURVIVOR; UREA BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PNEUMONIA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 78751483453     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emj.2009.089383     Document Type: Article

References (34)

1. Colice GL, Morley MA, Asche C, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004;125:2140-45. (Pubitemid 38788182)
2. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996;275:134-41.
3. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
4. Neil AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-16.
5. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
6. Smith RP, Lipworth BJ, Cree IA, et al. C-reactive protein A clinical marker in community-acquired pneumonia. Chest 1995;108:1288-91.
7. McIvor RA. Plasma d-dimer for outcome assessment in patients with CAP: not a replacement for PSI. Chest 2004;126:1015-16.
8. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004;126:1087-92.
9. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52:48-58.
10. Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128:2223-9.
11. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92:843-9.
12. Murray H, Cload B, Collier CP, et al. Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dyspnea. CJEM 2006;8:251-8.
13. Hall C. Essential biochemistry and physiology of (NT-pro) BNP [review]. Eur J Heart Fail 2004;6:257-60.
14. Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45. (Pubitemid 34833157)
15. Jernberg T, James S, Lindahl B, et al. Wallentin L. Natriuretic peptides in unstable coronary artery disease. Eur Heart J 2004;25:1486-93.
16. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of a plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005;112:527-34.
17. Morgenthaler NG, Struck J, Christ-Crain M, et al. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9:R37-45.
18. Binder L, Pieske B, Olschewski M, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005;112:1573-79. (Pubitemid 41324518)
19. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-35. (Pubitemid 37000195)
20. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;38:571-88.
21. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005;258:391-3.
22. Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the stratification of community-acquired pneumonia. J Intern Med 2008;264:166-76.
23. Yetkin O, Hacievliyagil SS, Gumen H. Assessment of B-type natriuretic peptide in patients with pneumonia. Int J Clin Pract 2008;62:488-91. (Pubitemid 351197405)
24. Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in emergency medicine research: where are the methods? Ann Emerg Med 1996;27:305-8.
25. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
26. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82.
27. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
28. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9. (Pubitemid 32718592)
29. Sumida H, Yasue H, Yoshimura M, et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 1995;25:1105-10.
30. Masson S, Vago T, Baldi G, et al. Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic in ambulatory patients with heart failure. Clin Chem Lab Med 2002;40:761-3.
31. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004;6:295-300. (Pubitemid 38253048)
32. Spindler C, Ortqvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. Eur Respir J 2006;28:816-23. (Pubitemid 46332004)
33. Ananda-Rajah MR, Charles PG, Melvani S, et al. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 2008;40:293-300. (Pubitemid 351447991)
34. Kollef KE, Reichley RM, Micek ST, et al. The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest 2008;133:363-9.